

15 February 2010

Media Release

New strong distribution partner for Italy and Romania

SWISS MEDICAL SOLUTION AG has entered into an exclusive Distribution Agreement with the Italian company SOFAR S.P.A. for the promotion, sales and distribution of U-Lab[®] in the markets of Italy and Romania.

In Italy U-Lab[®] has already been launched in December 2009 and in Q2 2010 it will also become available in Romania.

SOFAR S.P.A. is distributing as well CistiFlux (Cranberry), a product for the prevention of urinary tract infections (UTI).

Thanks to this cooperation, patients suffering from recurrent UTIs are offered the possibility to improve self management of their condition (prevention, diagnosis, treatment control). Unnecessary treatment with antibiotics may be avoided. U-Lab[®] is the first in-vitro diagnostic test for UTI, which has been specifically developed for the use by patients at home.

About SWISS MEDICAL SOLUTION AG

SWISS MEDICAL SOLUTION AG (SMS) is an innovative company focusing on the development, manufacturing and distribution of easy-to-use home diagnostic tests to detect urinary tract infections.

SMS has been founded under Swiss law and is located near Lucerne (Central Switzerland). It owns intellectual property rights to its U-Lab[®] technology platform. The first product, U-Lab[®], is already distributed in an increasing number of markets.

About SOFAR S.P.A.

SOFAR S.P.A. is an Italian family owned pharmaceutical company, founded in 1968 and located in Trezzano Rosa, about 30 km outside Milan. The company is specialized in the production and commercialization of medical products in the fields of dermatology, gastroenterology and gynaecology. The growing importance of bioactive nutritional supplements has led to the development of new products of clinical interest by SOFAR S.P.A. in that field. The company has a very high reputation in its home market Italy, but is also very successful in other markets like Romania.

About U-Lab

U-Lab[®] is a self test for home diagnosis of urinary tract infection (UTI) mainly for women, who are repeatedly suffering from that condition. It indicates the presence of nitrite as well as leucocytes in urine, in line with recommendations of international guidelines. Additionally it provides an integrated test validity indicator. It is the first and only test for UTI especially developed for the use by patients. It is easy and safe to use, the clear and easily readable test result will appear after 5 minutes and will remain visible for 24 hours, thus enabling the patient to share the result with her pharmacist or physician, if wished.

About Urinary Tract Infections

A urinary tract infection (UTI) is occurring when microorganisms, usually bacteria from the digestive tract, penetrate the urinary tract through the opening of the urethra and begin to multiply. Most infections arise from one type of bacteria, Escherichia coli, normally living in the colon. The urinary tract consists of the kidneys, the ureter, the bladder and the urethra. Each part may be affected. In case a UTI is left untreated, a permanent damage may occur to the bladder and kidneys. Antibiotic treatment is often required.

A UTI is a serious health problem affecting millions of women each year. It is the second most frequent infection (after respiratory tract infections). Nearly 40% of women develop UTI at least once in their life-time, about 80-90% of them will be affected a second time.

Approximately 5-10% of women suffer from frequent UTI. Three or more infections a year or two infections within six months are called recurrent UTI.

Contact for the Media

Dr. Thomas Kaltenbach
CEO Swiss Medical Solution AG
Werkstrasse
CH-6233 Büron
Office: + 41 41 935 41 11
Mobile: +41 79 285 7568
kaltenbach@swissmedicalsolution.ch

Further information and pictures under: www.swissmedicalsolution.ch